Provided by Tiger Trade Technology Pte. Ltd.

Soleno Therapeutics

30.05
-1.8100-5.68%
Post-market: 32.902.85+9.48%18:43 EDT
Volume:1.76M
Turnover:52.96M
Market Cap:1.55B
PE:77.05
High:32.37
Open:31.73
Low:29.43
Close:31.86
52wk High:90.32
52wk Low:29.43
Shares:51.62M
Float Shares:44.87M
Volume Ratio:1.11
T/O Rate:3.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3900
EPS(LYR):0.3900
ROE:6.01%
ROA:2.09%
PB:3.45
PE(LYR):77.05

Loading ...

Soleno Therapeutics (SLNO) Valuation Checked After New Q4 2025 Revenue Guidance

Simply Wall St.
·
Jan 22

Soleno Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jan 20

Soleno Therapeutics: Strong VYKAT XR Outperformance, Solid Balance Sheet, and Global Growth Optionality Drive Higher Buy-Rated Target

TIPRANKS
·
Jan 20

Stock Track | Soleno Therapeutics Plummets 5.06% Intraday After Baird Cuts Target Price

Stock Track
·
Jan 13

Cantor Fitzgerald Reaffirms Their Buy Rating on Soleno Therapeutics (SLNO)

TIPRANKS
·
Jan 13

Soleno Therapeutics (SLNO) Receives a Buy from Wells Fargo

TIPRANKS
·
Jan 13

Soleno Therapeutics: Sustained U.S. Vykat XR Outperformance and European Upside Support Buy Rating and $100 Target

TIPRANKS
·
Jan 13

Soleno Therapeutics price target lowered to $60 from $75 at Wolfe Research

TIPRANKS
·
Jan 13

BUZZ-U.S. STOCKS ON THE MOVE-AbCellera Biologics, Zymeworks, Silver miners

Reuters
·
Jan 12

Soleno Therapeutics Reverse Premarket Gains, Last Down 1.7%

THOMSON REUTERS
·
Jan 12

Soleno Therapeutics Preliminary Q4 Net Revenue Beats Analyst Estimates

MT Newswires Live
·
Jan 12

Soleno Therapeutics Projects 2025 Net Revenue of Up to $191 Million

Reuters
·
Jan 12

Soleno Therapeutics Inc Q4 REV View $81.7 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
Jan 12

Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results

THOMSON REUTERS
·
Jan 12

Soleno Therapeutics Inc - 2025 Net Revenue From US Sales of Vykat Xr Since Q2 Expected Between $189 Mln-$191 Mln

THOMSON REUTERS
·
Jan 12

Soleno Therapeutics Inc - Achieves Profitability and Positive Cash Flow

THOMSON REUTERS
·
Jan 12

Soleno Therapeutics Inc - Vykat Xr Discontinuation Rate Due to Adverse Events About 12%, as of Q4 End

THOMSON REUTERS
·
Jan 12

Will Peer‑Reviewed VYKAT XR Data Calm Safety Debate And Change Soleno Therapeutics' (SLNO) Narrative?

Simply Wall St.
·
Jan 09

Soleno Therapeutics Reports Positive Phase 3 Results for VYKAT XR in Prader-Willi Syndrome

Reuters
·
Jan 05

BUZZ-Oppenheimer starts Aardvark with 'outperform' on differentiated obesity franchise

Reuters
·
Dec 23, 2025